Amicus Therapeutics, Inc. (FRA:AM6)

Market Cap	3.72B +38.2%
Revenue (ttm)	510.28M +21.3%
Net Income	-11.98M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	23.04
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	246
Open	11.90
Previous Close	11.90
Day's Range	11.90 - 11.90
52-Week Range	4.80 - 12.30
Beta	n/a
RSI	57.80
Earnings Date	Feb 18, 2026

About Amicus Therapeutics

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration an...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 499
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: AM6

Financial Performance

In 2024, Amicus Therapeutics's revenue was $528.30 million, an increase of 32.29% compared to the previous year's $399.36 million. Losses were -$56.11 million, -62.99% less than in 2023.

Financial numbers in USD